Sanofi’s venglustat wins FDA breakthrough tag in type 3 Gaucher
Version 1
Sanofi said on March 18, 2026, that the US FDA granted Breakthrough Therapy designation to venglustat, its investigational oral glucosylceramide synthase inhibitor, for the treatment of neurological manifestations of type 3 Gaucher disease. The designation follows positive phase 3 LEAP2MONO data announced on February 2, 2026, in which once-daily oral venglustat met the primary endpoint and three of four key secondary endpoints versus intravenous enzyme replacement therapy in adults and pediatric patients ages 12 and older who had already reached therapeutic goals on enzyme replacement therapy. Sanofi said it plans global regulatory filings for the candidate. In the broader rare-disease regulatory landscape, the FDA also recently accepted Ultragenyx’s resubmitted biologics license application for UX111 (rebisufligene etisparvovec) in Sanfilippo syndrome type A, setting a September 19, 2026, PDUFA date and underscoring continued agency movement on high-need neurologic lysosomal and metabolic disorders. (sanofi.com)
Why it matters: For veterinary professionals tracking rare disease regulation and translational medicine, this is a reminder that FDA Breakthrough Therapy designation can materially speed sponsor-FDA interaction when preliminary clinical evidence suggests substantial improvement over available therapy. Type 3 Gaucher disease is the neuronopathic form of the disorder, with progressive neurologic signs layered onto systemic disease, so an oral therapy aimed at neurologic manifestations addresses a gap that standard enzyme replacement has struggled to solve because of limited central nervous system benefit. The UX111 filing acceptance adds context: the FDA is also engaging with other CNS-focused rare-disease programs backed by long-term follow-up, neurodevelopmental outcomes, and biomarker evidence. (fda.gov)
What to watch: The next step is whether Sanofi converts the phase 3 readout and Breakthrough designation into formal US and global filings, and what regulators say about the evidence package, label scope, and timeline. Across the space, rare-disease watchers will also be tracking Ultragenyx’s September 19, 2026, PDUFA date for UX111 and whether FDA’s handling of that application offers any read-through for neurologic endpoints, durability expectations, and manufacturing readiness in ultra-rare disease programs. (sanofi.com)